8-K: Exagen Secures Conditional NY Approval for New Biomarkers, Announces Record Preliminary 2024 Financial Results

Exagen Inc. has received conditional approval in New York for new lupus and rheumatoid arthritis biomarkers and reported record preliminary full-year 2024 revenue and improved adjusted EBITDA.

Summary

• Exagen has received conditional approval from the New York State Department of Health for new systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) biomarker assays.
• The commercial launch of these new biomarkers is planned for January 2025.
• These new biomarkers will be incorporated into the AVISE CTD platform, enhancing its clinical utility.
• Preliminary unaudited financial results for 2024 show record full-year revenue between $55.3 million and $55.8 million.
• The AVISE CTD trailing twelve-month average selling price (ASP) improved to between $408 and $412.
• Adjusted EBITDA for the full year 2024 improved by 37% to 43% compared to 2023, with a net loss between $14.8 million and $15.8 million.
• The company achieved net neutral cash usage in the fourth quarter of 2024.
• Exagen tested its 1,000,000th patient with AVISE CTD in 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the regulatory approval, record revenue, and improved profitability metrics. However, the preliminary nature of the results and the ongoing net loss temper the overall optimism.

Positives

• New York State approval for new SLE and RA biomarkers is a significant regulatory milestone.
• The planned commercial launch of new biomarkers in January 2025 provides a clear growth catalyst.
• Record full-year revenue indicates strong market demand for Exagen's testing services.
• The improvement in AVISE CTD ASP demonstrates the company's pricing power and value proposition.
• Significant improvement in adjusted EBITDA shows progress towards profitability.
• Net neutral cash usage in Q4 2024 indicates improved financial management.
• Reaching the 1,000,000th patient milestone is a testament to the success of AVISE CTD.

Negatives

• The preliminary financial results are unaudited and subject to change.
• The company reported a net loss between $14.8 million and $15.8 million for the full year 2024.
• Adjusted EBITDA is a non-GAAP measure and may not be directly comparable to other companies.

Risks

• The final financial results may vary from the preliminary results.
• Delays in reimbursement and coverage decisions from Medicare and third-party payors could impact revenue.
• The company's commercial success depends on market acceptance of its testing products.
• Failure to obtain and maintain intellectual property protection could harm the business.
• Regulatory developments could negatively affect the business.

Future Outlook

Exagen anticipates growth catalysts in 2025 with the launch of new biomarkers and continued progress towards profitability. The company expects to build on the momentum from 2024.

Management Comments

• John Aballi, CEO, stated that 2024 was a remarkable year for Exagen, highlighting the 1,000,000th patient tested with AVISE CTD.
• Mr. Aballi also noted the company's progress in optimizing operations and moving towards profitability.
• Mr. Aballi expressed excitement about the New York State approval and the growth catalysts for 2025.

Industry Context

The announcement aligns with the growing focus on precision medicine and the development of advanced diagnostic tools for autoimmune diseases. The new biomarkers aim to improve diagnostic accuracy and reduce the time to diagnosis, which is a key challenge in this field.

Comparison to Industry Standards

• Exagen's focus on autoimmune diagnostics is comparable to companies like Myriad Genetics and Veracyte, which also develop and commercialize specialized diagnostic tests.
• The improvement in adjusted EBITDA and revenue growth is a positive sign, but the company still needs to achieve profitability, which is a common challenge for companies in the diagnostic space.
• The 1,000,000th patient milestone is a significant achievement, indicating strong market adoption of AVISE CTD, which is a key differentiator compared to other diagnostic tests in the market.

Stakeholder Impact

• Shareholders will likely react positively to the record revenue and improved profitability metrics.
• Employees may be motivated by the company's progress and future growth prospects.
• Patients will benefit from the improved diagnostic capabilities of the new biomarkers.
• Clinicians will have access to more comprehensive diagnostic tools for autoimmune diseases.

Next Steps

• Commercial launch of new SLE and RA biomarkers in January 2025.
• Release of audited financial statements for the year ended December 31, 2024.

Key Dates

Keywords

autoimmune testing, biomarkers, rheumatoid arthritis, lupus, AVISE CTD, financial results, adjusted EBITDA, revenue, diagnostics, healthcare